MedWatch

Dako-CEO: Important and fast-growing business area

Dako’s recent collaboration agreement with Pfizer could lead to new products, says CEO Lars Holmkvist. It is the second major deal in a month and the CEO expects similar deals to follow.

Foto: Dako/PR

It is a long-term collaboration, it is profitable, it could lead to new products and it is a fast-growing business area, says Dako-CEO Lars Holmkvist about a recent collaboration agreement between the Danish company and the world’s largest pharmaceutical group, Pfizer.

“It is a collaboration that will run for several years and it is a wide-reaching agreement, through which Pfizer and Dako will work together on several aspects that have the potential to lead to new diagnostic products in our portfolio,” the CEO tells Medwatch and adds:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier